MedTrace Logo

I.V. Selonabant in Healthy Adult Subjects

NCT07211607 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-05-08

No results posted yet for this study

Summary

This is a Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous Selonabant in Healthy Adult Subjects Aged 18 to 30 Years

Conditions

  • Healthy Volunteers

Interventions

DRUG

selonabant

Intravenous infusion of selonabant

DRUG

placebo

Placebo infusion which looks the same as the selonabant infusion

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • Anebulo Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Sean Gilbey, MD · PPD Austin Clinical Research Unit

  • Rebecca Wood-Horrall, MD · PPD Austin Clinical Research Unit

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-09-22
Primary Completion
2026-05-06
Completion
2026-05-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07211607 on ClinicalTrials.gov